Combining Enzalutamide with Radium-223 Significantly Improves rPFS as First-Line Therapy for Patients with mCRPC By Ogkologos - August 27, 2025 582 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the PEACE-3 study Source RELATED ARTICLESMORE FROM AUTHOR EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate ESMO and ASCO publish joint consensus statement on streamlining clinical research FDA Grants Accelerated Approval to Camizestrant with a CDK4/6 Inhibitor for ESR1-Mutated HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer MOST POPULAR FDA Approves Pembrolizumab Combination for the First-Line Treatment of Cervical Cancer October 15, 2021 Selpercatinib Approved for Thyroid and Lung Cancers with RET Gene Alterations June 15, 2020 FDA Approves Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-positive, HER2-low or... March 6, 2025 EMA Adopts Positive Opinion for Pemetrexed Baxter November 3, 2022 Load more HOT NEWS Efficacy of ICI Combined with Chemotherapy in Patients with Advanced Penile... Indicators of Outcome Are Identified for Nivolumab Treatment of Patients with... Biomarkers of Pro-Inflammatory Response May Identifiy Cancer Patients at Risk of... COVID-19 Vaccine: Distribution and Administration
